Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension

Chinese Medical Journal

Volumn 126, Issue 7, 2013, Pages 1242-1246

  Guo, Jian Qiang ^a   Wang, Hong Yi ^a   Sun, Ning Ling ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Aliskiren; Arterial stiffness; Hypertension; Ramipril

Indexed keywords

ALISKIREN; RAMIPRIL;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; VASCULAR STIFFNESS;

EID: 84877318986     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20121927     Document Type: Article

References (20)

1. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
2. Ghiadoni L, Bruno RM, Stea F, Virdis A, Taddei S. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr hypertens Rep 2009; 11: 190-196.
3. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotens Aldosterone Syst 2004; 5: 102-108.
4. Volpe M, Pontremoli R, Borghi C. Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities. High Blood Press Cardiovasc Prev 2011; 18: 93-105.
5. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
6. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
7. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009; 27: 2022-2027.
8. Ito N, Ohishi M, Takagi T, Terai M, Shiota A, Hayashi N, et al. Clinical usefulness and limitations of brachial-ankle pulse wave velocity in the evaluation of cardiovascular complications in hypertensive patients. Hypertens Res 2006; 29: 989-995.
9. Wang X, Xie J, Zhang LJ, Hu DY, Luo YL, Wang JW. Reference values of brachial-ankle pulse wave velocity for Northern Chinese. Chin Med J 2009; 122: 2103-2106.
10. Zhu JR, Sun NL, Yang K, Hu J, Xu G, Hong H, et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertens Res 2012; 35: 28-33.
11. Hung CS, Lin JW, Hsu CN, Chen HM, Tsai RY, Chien YF, et al. Using brachial-ankle pulse wave velocity to associate arterial stiffness with cardiovascular risks. Nutr Metab Cardiovasc Dis 2009; 19: 241-246.
12. Mallareddy M, Parikh CR, Peixoto AJ. Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2006; 8: 398-403.
13. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Murohashi-Bokuda K, Itoh H. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res 2010; 33: 304-312.
14. Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004; 17: 1050-1055.
15. Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 2011; 26: 408-413.
16. Virdis A, Ghiadoni L, Qasem AA, Lorenzini G, Duranti E, Cartoni G, et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012; 33: 1530-1538.
17. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010; 33: 361-365.
18. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
19. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52: 563-572.
20. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovascr Pharmacol 1990; 15: 276-282.